Article 3 of 3
The results arrived on a Tuesday afternoon, in Kathleen’s patient portal, with no accompanying explanation. A column of numbers, reference ranges, flags for values outside those ranges, and the clinical equivalent of silence — no call from the office, no message from her doctor, just data sitting on a screen waiting to be interpreted by a woman who had spent three years feeling like a stranger in her own body.
She had done enough research by now to understand what she was looking at. Free T3 by LC-MS/MS: 2.1 pg/mL, low-normal by the reference range but meaningfully low in the context of her symptoms. Reverse T3: 28 ng/dL, elevated. The ratio, when she calculated it: 0.075 — well below the 0.2 threshold that suggests adequate deiodinase balance. Ferritin: 18 ng/mL. Vitamin D: 22 ng/mL. Selenium at the bottom quartile of reference range.
She printed the results. She made an appointment. And she walked into her primary care physician’s office with something she hadn’t had in three years: a coherent explanation for why she wasn’t getting better, and a starting point for what needed to change.
What followed was not a dramatic, overnight transformation. It was something more realistic and, in its own way, more meaningful — a carefully sequenced, collaborative process of addressing each finding in turn, adjusting her thyroid medication, correcting her nutritional deficiencies, and for the first time bringing her conventional medical care into genuine coordination with the functional medicine practitioner she had been seeing separately, in a parallel universe, for the better part of a year.
Six months later, Kathleen was teaching a business planning workshop. Her words came easily. The fog had lifted. She wasn’t pain-free, but the chronic ache in her joints had quieted from a shout to a murmur. She had stopped canceling things.
This article is about what happened in those six months — the treatment decisions, the evidence behind them, the role of functional medicine, and the structural changes that Southern Oregon’s healthcare ecosystem needs to make so that patients like Kathleen don’t have to wait three years, navigate two separate worlds of care, and do their own research just to receive treatment that the science has supported for years.
The Treatment Landscape: What the Evidence Actually Shows
Before we follow Kathleen’s treatment arc, we need to honestly map the evidence landscape — because this is where thyroid medicine is most hotly contested, most ideologically charged, and most in need of clear-eyed assessment.
There are, broadly speaking, three camps in the treatment of hypothyroidism.
The first camp — representing the majority of conventional endocrinologists and most clinical guidelines — holds that levothyroxine (synthetic T4) is the appropriate treatment for virtually all patients with hypothyroidism, that TSH normalization is the appropriate treatment target, and that patients who continue to feel unwell despite normalized TSH should be evaluated for other causes of their symptoms. This position has the weight of institutional authority behind it and reflects the care that the majority of hypothyroid patients receive.
The second camp — found more often in functional and integrative medicine practices — holds that desiccated thyroid extract (DTE, the dried thyroid gland of pigs, containing both T4 and T3 in a roughly 4:1 ratio) is the more physiologically complete replacement, that TSH is an inadequate treatment target, and that comprehensive biomarker assessment including free T3 and reverse T3 should guide dosing. This position has a passionate patient following, some supporting research, and legitimate scientific grounding — but also exists in a space where overclaiming and inadequate evidence sometimes coexist with genuine insight.
The third camp — smaller, but scientifically rigorous — holds that the right answer is nuanced: that levothyroxine is appropriate and effective for most patients, that combination T4/T3 therapy (either synthetic or as desiccated thyroid extract) is warranted for a meaningful minority who fail levothyroxine monotherapy, and that the treatment target should be not just biochemical normalization but symptomatic resolution. This is the position articulated by Antonio Bianco and increasingly reflected in updated professional guidelines.
The evidence, examined carefully, supports the third position. Let’s look at why.
Levothyroxine: Where It Works and Where It Falls Short
Levothyroxine is, for the majority of patients with hypothyroidism, a genuinely effective treatment. This bears stating clearly, because in the current environment of polarized thyroid debate, it is easy for the legitimate critiques of levothyroxine to be mistaken for an argument that it doesn’t work. It works. For approximately 80-85% of hypothyroid patients, T4 monotherapy normalizes TSH, resolves the major symptoms of hypothyroidism, and restores quality of life to baseline. The drug has a long half-life of approximately eight days, which makes it forgiving — you can miss a dose without consequence, take two the next day, and your body barely notices. It is stable, consistent in potency, and easy to manage.
The problem is the 15-20% for whom it doesn’t work well enough. And the further problem — identified in the large retrospective study Antonio Bianco published comparing over a million treated hypothyroid patients with a matched healthy population — is that even in the patients who feel well on levothyroxine, mortality remains elevated. The treated hypothyroid population dies at roughly 2.5 times the rate of healthy controls, primarily from cardiometabolic causes. This is a signal that demands explanation, and the most compelling explanation is this: levothyroxine normalizes the pituitary-thyroid feedback loop and satisfies the TSH thermostat, but it does not reliably restore T3 levels to the tissues that need it most.
The liver is the most clearly documented example. In animal models, rats treated with levothyroxine sufficient to normalize TSH show persistent hypothyroidism in the liver — reduced LDL receptor expression, impaired cholesterol clearance, elevated circulating LDL. This is almost certainly what underlies the clinical observation that statins are the most commonly co-prescribed medication with levothyroxine. The cholesterol goes up in hypothyroidism. Levothyroxine normalizes TSH. The cholesterol often does not fully normalize. The patient goes on a statin. The physician considers the thyroid treated and moves on.
But the question nobody has formally asked in a prospective trial — and this is a remarkable gap given that we are talking about 20 million patients in the United States — is whether combination T4/T3 therapy would normalize cholesterol more effectively than levothyroxine alone. Whether it would reduce cardiovascular events. Whether it would reduce mortality. The retrospective data strongly suggests it would. The prospective trial has not been run.
The Case for Combination Therapy: What the Research Shows
The evidence for combination T4/T3 therapy — whether synthetic (levothyroxine plus liothyronine) or as desiccated thyroid extract — has been building for years, and while it is not yet sufficient to support universal adoption, it is more than sufficient to support its use in patients who fail levothyroxine monotherapy.
The foundational argument is physiological: the normal human thyroid secretes both T4 and T3, in a ratio of approximately 4:1 (80% T4, 20% T3). Replacing only the prohormone (T4) and trusting entirely in peripheral conversion to supply T3 is a workable strategy most of the time, but it asks the deiodinase system to do something the body was not designed to do — supply 100% of T3 needs from peripheral conversion, rather than the roughly 80% it supplies in a person with a functioning thyroid. In patients whose deiodinase function is impaired — by inflammation, by nutritional deficiency, by genetic variation in deiodinase genes, by the chronic stress of autoimmune disease — this demand may not be met.
The patient preference data is striking. In blinded crossover studies — where patients don’t know which treatment they’re receiving — patients consistently prefer combination therapy to levothyroxine alone, by a ratio of approximately 2:1. This is not a small effect. People who cannot be influenced by expectation or placebo, because they don’t know what they’re taking, are telling us in significant numbers that combination therapy makes them feel better. That is clinically meaningful signal.
The mortality data from Bianco’s retrospective study — a 30% reduction in all-cause mortality in patients taking combination therapy compared to levothyroxine alone — represents the most compelling large-scale evidence to date. As discussed in Article 2, this was a carefully controlled analysis with propensity score matching for comorbidities, and the two populations were comparable at baseline. A 30% mortality reduction is the kind of effect size that, in virtually any other therapeutic area, would trigger urgent calls for a prospective confirmatory trial. In thyroid medicine, it has been met with cautious acknowledgment and continued debate.
Why the reluctance? Partly inertia — levothyroxine has been standard of care for decades and changing that standard requires overcoming enormous institutional momentum. Partly the legitimate concern about the pharmacokinetics of T3 — its short half-life of roughly 12 hours means that oral T3 produces peaks and troughs in circulation that don’t mimic the steady T3 supply the body produces endogenously. Partly the historical association of T3 with side effects: palpitations, anxiety, bone loss, atrial fibrillation. These side effects are real — but they are almost exclusively associated with excessive T3 dosing, not with carefully calibrated combination therapy at physiological replacement doses.
And partly, it must be said, commercial inertia. Levothyroxine is one of the most prescribed drugs in America. The market incentive to study a competitor is limited.
Desiccated Thyroid Extract: Sorting Evidence From Ideology
Desiccated thyroid extract deserves its own careful discussion, because it sits at the intersection of legitimate science and extraordinary cultural fervor — and it is nearly impossible to have a calm, evidence-based conversation about it without someone on one side or the other getting heated.
The facts: DTE is a standardized powder of porcine (pig) thyroid gland, containing T4 and T3 in a ratio of approximately 3.5 to 4:1. It has been used to treat hypothyroidism since approximately 1900 — predating the FDA, predating the isolation of levothyroxine in 1914, predating essentially everything we now know about thyroid physiology. It was grandfathered into regulatory use rather than approved through the modern clinical trial pathway. Its potency is standardized by the United States Pharmacopeia to within ±10%, a standard that was further tightened with the adoption of mass spectrometric potency measurement in 1985.
The safety concerns historically raised against DTE — that the T3 spike after oral ingestion causes transient hyperthyroidism, damages the heart, accelerates bone loss — have not been borne out in controlled trials. Safety profiles in head-to-head studies are equivalent to levothyroxine. The 2013 double-blind crossover trial by Hoang and colleagues found that 48.6% of patients preferred DTE, compared to 18.6% who preferred levothyroxine, with the remainder expressing no preference. A 2021 three-arm trial comparing levothyroxine, synthetic T4/T3 combination, and DTE found similar preferences for the two combination approaches over monotherapy.
There are approximately 1.5 million patients in the United States currently taking DTE, and approximately 400,000 taking synthetic combination therapy. These are not fringe numbers. These are patients who, in significant proportions, found their way to combination therapy because levothyroxine alone was insufficient.
The legitimate concerns about DTE are practical, not ideological. The T4:T3 ratio in pig thyroid (approximately 3.5-4:1) is fixed and cannot be adjusted — which is a limitation when a patient needs a different ratio. The T3 component, because it has a 12-hour half-life, does produce a post-dose peak that some patients feel as a brief period of stimulation; for some, this is uncomfortable. Manufacturing quality, while regulated, varies between brands. The FDA has issued recalls for both DTE and levothyroxine products over the years, and patients taking DTE should be aware of and check for current recalls.
The bottom line on DTE: it is a legitimate, evidence-supported treatment option for patients who prefer combination therapy or who have failed levothyroxine monotherapy. It is not a miracle cure. It is not appropriate for every patient. And the ideological fervor with which some practitioners and patient communities promote it — as the only natural, correct, human approach to thyroid replacement — serves neither patients nor the evidence base well.
The Slow-Release T3 Problem: Why the Future of Thyroid Treatment Isn’t Here Yet
The central pharmacological problem with oral T3 — in any formulation, synthetic or as DTE — is the peak-and-trough dynamic produced by its 12-hour half-life. A normal thyroid doesn’t dump T3 into the bloodstream in a single daily bolus. It secretes small amounts continuously throughout the day, producing a stable, steady supply to peripheral tissues. Oral T3, however it’s packaged, produces a pulse of circulating T3 that rises sharply after ingestion and then falls — creating a period of relative excess followed by a period of relative deficit.
This is why the holy grail of thyroid pharmacology is a slow-release T3 formulation — something that would mimic the thyroid’s continuous secretion pattern and produce stable T3 levels throughout the day. Two promising approaches are currently in development.
The first, being developed in the United States, uses a polymer matrix in which T3 is embedded and released gradually as the polymer breaks down in the intestine. Phase I clinical trials have been completed successfully, and the developer is working with the FDA through the 505(b)(2) regulatory pathway — an accelerated route available when a new formulation contains the same active molecule as an already-approved drug. This pathway could substantially shorten the approval timeline.
The second approach, being investigated in Europe, uses T3 sulfate — an inactive form of T3 that is absorbed orally and then converted to active T3 by a liver enzyme called sulfatase, which operates at a steady, rate-limited velocity. Because sulfatase converts T3 sulfate to T3 at a constant rate regardless of how much T3 sulfate is present, the liver becomes a continuous, self-regulating source of T3 to the circulation — precisely the physiological mimicry that current oral T3 cannot achieve.
Neither of these products is available to patients today. But their development represents the direction thyroid pharmacology needs to move — toward treatments that don’t just replace the molecule but replicate the physiological delivery pattern. When slow-release T3 becomes available, it will likely transform the calculus of combination therapy, removing the peak-and-trough concern that is the most legitimate objection to T3-containing regimens.
In the meantime, clinicians and patients working with currently available treatments should understand that the absence of a perfect slow-release T3 does not make combination therapy inappropriate — it makes careful dosing and timing important. Many patients manage T3-containing regimens very well with split dosing — taking their T3 component twice daily rather than once, to smooth the pharmacokinetic curve.
What Functional Medicine Gets Right — and Where the Evidence Gets Thin
Southern Oregon’s functional medicine community has been, in many cases, ahead of the conventional medical establishment on thyroid care. The willingness to measure free T3 comprehensively, to check nutritional cofactors, to address the autoimmune dimension of Hashimoto’s, to consider combination therapy when monotherapy fails, to spend time understanding a patient’s full physiological context — these are genuine clinical contributions, and the patients who have benefited from them deserve acknowledgment.
But intellectual honesty requires examining where functional medicine’s thyroid practices are well-supported and where they venture beyond the evidence.
Well-supported functional medicine interventions:
Selenium supplementation in Hashimoto’s. Multiple randomized controlled trials have demonstrated that selenium supplementation (typically 200 mcg daily of selenomethionine) reduces anti-TPO antibody titers in Hashimoto’s patients and may slow the progression of thyroid destruction. The mechanism is understood — selenium is a structural component of the deiodinase enzymes, and selenium has direct antioxidant effects on the thyroid peroxidation reactions that generate thyroid-damaging free radicals. The evidence is sufficient to support this intervention as a standard recommendation in Hashimoto’s.
Vitamin D optimization. Low vitamin D is associated with higher anti-TPO titers and more aggressive autoimmune thyroid disease. Supplementation to achieve 25-hydroxyvitamin D levels of 50-80 ng/mL is low-cost, low-risk, and supported by mechanistic and observational evidence. It is unlikely to cause harm and likely to provide benefit.
Iron and ferritin repletion. Treating iron deficiency in hypothyroid patients is not controversial — it is simply good medicine. The overlap between iron deficiency symptoms and hypothyroid symptoms is clinically important, and iron repletion can produce meaningful symptom improvement independent of thyroid hormone changes.
Dietary anti-inflammatory approaches. The inflammatory burden of autoimmune disease — including Hashimoto’s — is influenced by diet. Anti-inflammatory dietary patterns (broadly: whole foods, adequate protein, omega-3 fatty acids, limited ultra-processed foods) are supported by substantial evidence in the context of autoimmune disease broadly, and by plausible mechanistic reasoning in Hashimoto’s specifically. No single dietary intervention has been proven in large thyroid-specific trials, but the direction of evidence is consistent.
Gluten elimination in patients with concurrent celiac disease or non-celiac gluten sensitivity. The relationship between celiac disease and autoimmune thyroid disease is well-documented — they co-occur at significantly higher rates than chance, and treatment of celiac disease with a gluten-free diet can reduce anti-TPO titers. In patients without celiac disease or documented gluten sensitivity, the evidence for gluten elimination is much weaker, and the recommendation should not be made universally.
Stress reduction and sleep optimization. Chronic psychological stress and sleep deprivation elevate cortisol and inflammatory cytokines, which suppress D1 activity, shift the T4-to-T3 conversion balance toward reverse T3, and amplify autoimmune activity. This is not soft advice — it is mechanistically grounded in the deiodinase physiology we have described throughout this series. For patients whose reverse T3 is elevated in the context of chronic stress, addressing the stress is as therapeutically relevant as adjusting the medication.
Where the evidence thins:
Very high-dose iodine supplementation. There is a significant faction in functional and integrative thyroid medicine that advocates for high-dose iodine — doses of 12.5 mg to 50 mg daily, orders of magnitude above the recommended dietary intake of 150 mcg. The theoretical justification involves saturating thyroid iodine uptake to prevent thyroid cancer and support hormone production. The evidence does not support this practice, and the evidence against it is meaningful. High iodine intake increases the antigenicity of the thyroid, can precipitate or worsen autoimmune thyroid disease, and can trigger iodine-induced hyperthyroidism in patients with nodular thyroid disease. Japan, where dietary iodine intake averages 500-600 mcg daily — well above Western levels but far below supplement-dose recommendations — has a measurably higher incidence of autoimmune thyroid disease than iodine-sufficient but not iodine-excessive populations. Recommending high-dose iodine supplementation to hypothyroid patients is not supported by evidence and carries real risk.
Compounded controlled-release T3. As discussed briefly in Article 1’s context, compounding pharmacies across the country offer “slow-release” T3 preparations as an alternative to pharmaceutical-grade liothyronine. The appeal is clear — the idea of avoiding T3 peaks by delivering it slowly is pharmacologically sound. The problem is that there is not a single published study demonstrating that any compounded controlled-release T3 preparation actually produces a slow-release pharmacokinetic profile. One study that tested a product claiming slow-release characteristics found it to be pharmacokinetically identical to standard immediate-release T3. Compounding pharmacy quality control for a substance measured in micrograms is technically challenging even for reputable pharmacies, and the accuracy and consistency of compounded T3 preparations cannot be assumed. Until a compounded product demonstrates slow-release pharmacokinetics in published peer-reviewed data, patients and physicians should be cautious about this option — even from high-quality compounding pharmacies.
Blanket condemnation of levothyroxine as “unnatural” or universally inadequate. Some functional medicine practitioners present levothyroxine as categorically inferior to DTE and frame T4 monotherapy as a pharmaceutical industry conspiracy against patient health. This is not supported by evidence, is harmful to patients who are doing well on levothyroxine, and undermines the credibility of legitimate critiques of standard thyroid care. Levothyroxine works well for most patients. The evidence supports adding T3 for the minority who fail monotherapy — not abandoning T4 therapy for everyone.
The Integrated Approach: How Kathleen’s Care Finally Came Together
When Kathleen brought her extended lab results to her PCP, the conversation that followed was different from any she’d had in three years. Different not because her doctor had changed, but because both of them were now working from the same map.
Her physician recognized that the depleted ferritin and vitamin D needed to be addressed first — before adjusting her thyroid medication — because both deficiencies were likely contributing to her symptoms independently, and because correcting them would allow a cleaner assessment of how her thyroid medication was actually performing. Kathleen began iron supplementation, targeted to bring ferritin above 70 ng/mL. She started vitamin D3 at 5,000 IU daily with K2, with a recheck planned at 90 days. Selenomethionine at 200 mcg daily was added based on her low-normal selenium and her Hashimoto’s diagnosis.
Her PCP also made a phone call — a conversation that had never happened before in Kathleen’s care — to the functional medicine practitioner Kathleen had been seeing. They compared notes. The functional medicine provider had already been recommending an anti-inflammatory dietary approach and was working with Kathleen on sleep hygiene and stress management. They agreed on a shared set of biomarkers to track, a shared timeline for reassessment, and a division of clinical responsibility that made sense: the PCP would manage the medication and monitor cardiovascular risk; the functional medicine provider would continue supporting the lifestyle interventions and nutritional optimization.
At the three-month mark, Kathleen’s ferritin had risen to 52 ng/mL. Her vitamin D was 58 ng/mL. She felt somewhat better — more energy, slightly clearer cognition — but not yet where she wanted to be. Her free T3 had improved slightly, from 2.1 to 2.6 pg/mL, but her reverse T3 remained elevated at 24 ng/dL. Her ratio had improved from 0.075 to 0.108, but was still below 0.2.
The decision was made to transition from Armour Thyroid — which she had been on at a dose that wasn’t optimized — to a synthetic combination of levothyroxine and low-dose liothyronine. The rationale was that synthetic combination therapy allows for precise adjustment of the T4:T3 ratio in a way that DTE does not. Her physician started her on a ratio of approximately 4:1 T4 to T3, with the T3 dose split into morning and early afternoon to minimize the pharmacokinetic peak.
At the six-month mark, Kathleen’s free T3 was 3.2 pg/mL. Reverse T3 had fallen to 15 ng/dL. Her ratio was 0.213 — just above the threshold, for the first time. Her TSH was 1.4. Her LDL, which had been running elevated, had come down by 18 points without any change to her statin therapy. Her anti-TPO antibodies, which had been 340 IU/mL at diagnosis three years earlier, were now 180 IU/mL — still elevated, but trending meaningfully downward.
And Kathleen was teaching that workshop. Her words came easily. She had stopped canceling things.
What Southern Oregon Needs to Build
Kathleen’s outcome was good. But the process that produced it — three years of inadequate treatment, a patient doing her own research, a by-chance encounter with the right book, an advocacy conversation with her physician, a phone call between two providers who had never spoken — is not a system. It is a series of accidents in a patient’s favor. And for every Kathleen who figures it out, there are dozens who don’t. Who accept the “your labs are normal” verdict. Who go on antidepressants for what is actually undertreated hypothyroidism. Who spend years attributing their symptoms to aging, stress, or personal failing.
Southern Oregon can do better. Here is what better looks like, structurally and practically.
A shared diagnostic protocol. The most immediately actionable change would be the adoption of a standardized, comprehensive thyroid panel by primary care practices across the region — one that includes free T3 by LC-MS/MS, reverse T3, anti-TPO and anti-Tg antibodies, and nutritional cofactors as the baseline workup for any patient with hypothyroidism or persistent hypothyroid-type symptoms. This doesn’t require new infrastructure. It requires agreement — a shared protocol, championed by regional medical leadership, that establishes a higher standard of diagnostic comprehensiveness.
Care coordination pathways between conventional and functional medicine. The parallel-silo problem — conventional and functional medicine operating on separate tracks with no communication — is solvable with relatively modest investment. Shared care plan templates, a regional secure messaging system that crosses practice boundaries, or even agreed-upon referral protocols that include specific information exchange requirements would allow the two communities to reinforce rather than ignore each other. Reimagine Healthcare is positioned to facilitate this — not as a regulatory body, but as a convener. A regular case conference, a shared educational forum, a working group on thyroid care standards: any of these would begin to build the connective tissue the region lacks.
Insurance advocacy for comprehensive lab testing. Free T3 by LC-MS/MS and reverse T3 are not exotic tests. They are available through major reference laboratories. But insurance coverage is inconsistent, and the prior authorization burden for non-standard panels can deter even motivated physicians from ordering them. Patient advocacy organizations, regional medical societies, and healthcare system leadership can collectively push for coverage standardization — making the case that the cost of comprehensive testing is far less than the cost of years of inadequately treated hypothyroidism, its cardiometabolic complications, its psychiatric co-morbidities, and its impact on workforce productivity.
Continuing medical education focused on thyroid complexity. The PCPs of Southern Oregon were trained in a framework that has been substantially updated by the research of the past two decades. That is not their fault — it is the nature of medical knowledge evolving faster than medical education. But it creates a genuine gap between what the science supports and what patients receive. Regional CME programs, grand rounds presentations at Asante and Providence, and educational collaborations between conventional and functional medicine practitioners can begin to close that gap. The goal is not to convert every PCP to a thyroid specialist — it is to raise the floor of thyroid literacy enough that patients like Kathleen don’t fall through it.
A prospective registry. One of the most valuable things Southern Oregon could contribute to the national thyroid conversation is data. A voluntary registry of hypothyroid patients — tracking biomarkers, treatment approaches, symptom outcomes, and quality of life over time — would provide the kind of real-world longitudinal evidence that prospective clinical trials are too expensive and too slow to generate. This kind of registry, operated through a collaborative of regional practices, could answer questions that academic research hasn’t gotten to: What are the outcomes of comprehensive versus standard testing? What is the real-world response rate to combination therapy versus monotherapy? What is the relationship between anti-TPO trajectory and long-term cardiometabolic outcomes? Southern Oregon has the patient population, the motivated practitioners, and — through Reimagine Healthcare — the organizational infrastructure to make something like this possible.
A Treatment Roadmap for PCPs and Patients
To close this series with the concrete guidance we promised in Article 1, here is the integrated treatment roadmap that the evidence supports.
For PCPs — the Monday morning protocol:
When a patient presents with hypothyroidism or persistent hypothyroid-type symptoms:
Start with the comprehensive panel described in Article 2: TSH, free T4, free T3 by LC-MS/MS, reverse T3, anti-TPO, anti-Tg, ferritin, 25-hydroxyvitamin D, selenium.
Address nutritional deficiencies before or concurrent with medication adjustment. Depleted ferritin (below 70 ng/mL), low vitamin D (below 50 ng/mL), and low selenium can all independently impair thyroid hormone conversion and produce symptoms that look like undertreated hypothyroidism. Correcting them is low-cost, low-risk, and may substantially improve symptoms without medication changes.
Start most patients on levothyroxine. It works for the majority and has a well-characterized safety profile. Titrate to a TSH in the lower half of the reference range — closer to 1.0-2.0 mIU/L rather than 3.0-4.0 — while monitoring free T3 and free T4 to ensure the tissue-level picture is improving alongside TSH normalization.
When a patient on adequate levothyroxine continues to have symptoms, don’t immediately attribute this to other causes. Check free T3 by LC-MS/MS and reverse T3 first. A low-normal free T3 with elevated reverse T3 and a ratio below 0.2 is a signal that peripheral conversion is insufficient and that combination therapy deserves consideration.
For combination therapy, synthetic T4 plus liothyronine at a ratio of approximately 4:1 is the most flexible option — it allows precise dose adjustment that DTE does not. Start with a low liothyronine dose (typically 5 mcg) split into two daily doses to minimize peak-trough dynamics. For patients who prefer DTE or who have done well on it, it remains a legitimate option — check for current FDA recalls and use established brands.
Treat hypothyroidism as a cardiometabolic risk factor. Monitor LDL, apoB, blood pressure, and cardiovascular risk markers with the same attention you would give a patient with established metabolic syndrome. Don’t assume normalization of TSH means normalization of cardiometabolic risk.
Track anti-TPO antibodies annually. A declining trend suggests the autoimmune process is being modulated — perhaps by selenium, vitamin D, dietary changes, or stress reduction. A rising trend warrants more aggressive attention to lifestyle and nutritional factors, and possibly discussion of emerging immunomodulatory approaches.
Consider a phone call to your patient’s functional medicine provider if they have one. The conversation takes ten minutes. The value to the patient — integrated, non-duplicative, non-contradictory care — is enormous.
For patients — the advocacy roadmap:
At your next thyroid appointment, ask for the extended panel described in Article 2. Frame it as wanting to understand the full picture, not as a challenge to your physician’s competence. Most PCPs, when presented with a patient who has done careful research and is asking for specific, evidence-based tests, will engage constructively.
If your free T3 by LC-MS/MS comes back low-normal and your reverse T3 is elevated, ask your physician to discuss what this means for your treatment plan. Ask specifically: “Is it possible that my TSH looks normal because my pituitary is satisfied, even though my peripheral tissues aren’t getting enough T3?”
If you have a functional medicine provider, bring them into the conversation with your PCP. Share records between them. Ask explicitly whether they can communicate with each other. You should not have to be the sole conduit of information between your own healthcare providers.
If you are on levothyroxine and continuing to feel unwell despite normalized labs, ask about the evidence for combination therapy. You are entitled to know that the option exists, that blinded clinical trials show patient preference for combination therapy at a ratio of roughly 2:1, and that a recent large-scale study found a 30% reduction in all-cause mortality with combination versus monotherapy.
Correct your nutritional deficiencies. Get your ferritin above 70 ng/mL. Get your vitamin D to 50-80 ng/mL. Ensure adequate selenium intake — either through diet (two to three Brazil nuts daily provides approximately the right amount) or through supplementation at 200 mcg selenomethionine daily. These are not optional lifestyle enhancements. They are prerequisites for your thyroid medication to work.
Take the inflammatory burden seriously. If you are under chronic psychological stress, sleeping poorly, eating in ways that sustain inflammation, or carrying significant metabolic dysfunction, your deiodinase system is being suppressed by forces that medication cannot fully compensate for. The lifestyle interventions that functional medicine emphasizes — stress reduction, sleep optimization, anti-inflammatory diet, regular physical activity — are mechanistically grounded in thyroid physiology. They are not soft add-ons. They are part of the treatment.
The Larger Argument
Kathleen’s story is, in the end, a story about information asymmetry. Her physicians had information she didn’t — about the limitations of their standard approach, about the existence of tests that could tell a more complete story, about the evidence for treatments beyond levothyroxine. She had information they didn’t — about what it felt like to live in her body, about the gap between what the numbers said and what her life looked like, about the three years of diminishment that the labs had declared acceptable.
Good medicine happens when both kinds of information are in the room at the same time. When the patient’s lived experience is treated as data, not dismissed as anxiety. When the physician’s training is a starting point for inquiry, not a closed file. When the biochemistry and the biography inform each other.
The thyroid system, as we have explored across these three articles, is not simple. It is a dynamic, tissue-specific, enzymatically regulated network that plays out at a level of biological complexity that no single blood test can fully capture. The science has moved substantially beyond the TSH-and-T4 framework that still governs most clinical practice. The gap between what the research supports and what most patients receive is real, measurable, and — for a meaningful number of people — consequential.
Southern Oregon has everything it needs to close that gap: motivated practitioners on both sides of the conventional-functional divide, a patient population hungry for better answers, and a regional healthcare infrastructure that is small enough to change and large enough to matter. What it needs now is the will to build the connective tissue — the shared protocols, the integrated care pathways, the educational infrastructure, the data systems — that turn individual motivated practitioners into a system that reliably serves patients like Kathleen.
Not after three years. From the beginning.
Key Takeaways — Article 3
- Levothyroxine is effective for approximately 80-85% of hypothyroid patients. The 15-20% who continue to feel unwell deserve a different approach, not a different explanation for why their suffering is acceptable.
- Combination T4/T3 therapy — synthetic or as desiccated thyroid extract — is supported by patient preference data, physiological evidence, and a large retrospective study showing 30% reduction in all-cause mortality compared to levothyroxine monotherapy. It should be offered to patients who fail monotherapy.
- Desiccated thyroid extract is a legitimate treatment option with a standardized potency, equivalent safety to levothyroxine, and significant patient preference in blinded trials. Ideological fervor on either side of the DTE debate is not well-served by the evidence.
- Compounded slow-release T3 does not have published pharmacokinetic evidence supporting its slow-release claims. Caution is warranted. Pharmaceutical slow-release T3 is in development and represents the future of combination therapy.
- Functional medicine interventions with meaningful evidence in Hashimoto’s include: selenium supplementation, vitamin D optimization, iron repletion, anti-inflammatory diet, gluten elimination in celiac/gluten-sensitive patients, and stress and sleep optimization. High-dose iodine is not supported and carries risk.
- Hypothyroidism is a cardiometabolic risk factor. Treating it requires attention to lipids, cardiovascular risk, and the inflammatory burden of autoimmune disease — not just TSH normalization.
- Southern Oregon needs shared diagnostic protocols, care coordination pathways between conventional and functional medicine, insurance advocacy for comprehensive testing, targeted continuing medical education, and a prospective outcomes registry.
- Good thyroid care requires both the physician’s biochemistry and the patient’s biography. Closing the information asymmetry between them is the work.
This concludes the Reimagine Healthcare three-part series on thyroid disease. A companion clinical reference card summarizing the recommended diagnostic panel and treatment roadmap is available for download at reimagine-healthcare.org.
Editorial Disclaimer
This article is investigative health journalism produced by Reimagine Healthcare, a Southern Oregon initiative dedicated to closing the gap between emerging medical evidence and everyday clinical practice. It is not medical advice, does not constitute a clinical recommendation, and is not a substitute for the individualized care of a licensed healthcare provider. The information presented here is drawn from peer-reviewed research, published scientific literature, and the work of recognized experts in thyroid physiology. Readers are encouraged to use this material to inform conversations with their own physicians — not to replace them. If you have concerns about your thyroid health, please consult a qualified medical professional. Reimagine Healthcare does not endorse any specific laboratory, pharmacy, supplement, or treatment protocol.